Kline Lab

Very excited to share our lab's work is now out in print @JCO_ASCO! All-star lab member Alan Cooper and others develop a CD5 gene signature (CD5sig) that shows a selective EFS+OS benefit for CD5sig+ DLBCLs treated with R-CHOP+ibrutinib in PHOENIX trial... ascopubs.org/doi/abs/10.120…

Today at #ASH24, @AlexandraRojek presented excellent study demonstrating how PI3Kγ/δ inhibitors can delay terminal CAR T cell differentiation, an innovative approach to enhance the efficacy of CAR T cell therapy. @KlineLabUChi @UChicagoHemOnc @UChicagoLeuk

We’re excited to see outstanding science talks at the Jonas Center for Cellular Therapy Symposium today @UChicagoHemOnc and updates on our lab’s work shared by Dr. Kline!

Justin Kline, MD chairs an oral abstract session -"Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia" and Peter A. Riedell, MD discusses 3 abstracts in the same session. @KlineLabUChi @UCCancerCenter @UChicagoCCB

🌟Exciting news alert! Scott Oakes, MD has been named Vice Dean for Clinical Science Research of @UChicagoBSD & @UChiPritzker. His expertise and leadership will undoubtedly elevate research efforts to new heights. Join us in congratulating him on this well-deserved appointment!🎉

🚨Fantastic pair of papers in @Nature today from @EvanWeberPhD, @MackallLab and the Darcy lab @PeterMacCC on enforcing stem-like molecular programs in therapeutic T cells through overexpression of #FOXO1! 👇 nature.com/articles/s4158…. @ChildrensPhila @StanfordCancer @parkerici

Sidney Wang, grad student in Kline’s lab presents excellent poster at #AACR24 showing PRDM1 as a potential therapeutic target to enhance CAR-T therapy efficiency in large B-cell lymphoma. #NationalCancerPlan #Every1HasARole @UCCancerCenter @UChicagoHemOnc @theNCI @KlineLabUChi

Joanna Chorazeczewski, graduate student from Kline’s lab presents excellent data on the mechanisms underlying the bystander killing by CAR Tcells. @UCCancerCenter @UChicagoCCB @UChicagoCOI

Functional, expanded T cells may be responsible for #ICB success in classical Hodgkin lymphoma according to new research in @CIR_AACR from @KlineLabUChi and team. @UChicagoMed @UChicagoHemOnc #cHL #lymsm ow.ly/KZSO50R9och

Huge congratulations to Pete Savage, PhD, Associate Professor of Pathology on his new appointment as chair of the Committee on Immunology (@UChicagoCOI). His leadership in COI and @UCCancerCenter is invaluable. #CancerResearch #Immunology 🧬🔬 ow.ly/qBQM50R7NwV

With #AACR24 approaching, make sure to check out fantastic posters presented by 2 of our lab members on CAR T cell therapy! aacrjournals.org/cancerres/arti… presented by grad student @jchorazeczewski aacrjournals.org/cancerres/arti… presented by grad student Sidney Wang! @UChicagoHemOnc

Here, Justin Kline, MD, @UCCancerCenter, @UChicagoMed, discussed a novel CD5 gene expression signature (CD5sig) that is a useful biomarker to identify #DLBCL subtypes vulnerable to #BTK inhibitor therapies. Learn more: hmpgloballearningnetwork.com/site/onc/video… #MedTwitter #Oncology #OncologyNews

Congratulations to Dr. Kline & team on a great new article on single-cell phenotyping of the classic Hodgkin lymphoma (cHL) environment, with results that shed new light on the nature of T cells: aacrjournals.org/cancerimmunolr… @AACR @UChicagoMed @UCCancerCenter #lymphoma #Tcells

CD5 represents an easy and exportable biomarker, appears to be a surrogate for molecular subtypes in DLBCL, and should be characterized in ongoing and future studies of targeted agents that perturb BCR signaling. @JCO_ASCO ascopubs.org/doi/full/10.12…

@gvencut1 @SoniSmithMD @jovianyu @UChicagoHemOnc @UCCancerCenter

Thus, CD5sig is a useful biomarker to identify DLBCLs vulnerable to BTKi-based therapies and complements current biomarker approaches by identifying DLBCLs with genetic and non-genetic bases for BTKi sensitivity

Very excited to share our lab's work is now out in print @JCO_ASCO! All-star lab member Alan Cooper and others develop a CD5 gene signature (CD5sig) that shows a selective EFS+OS benefit for CD5sig+ DLBCLs treated with R-CHOP+ibrutinib in PHOENIX trial... ascopubs.org/doi/abs/10.120…

🚀 Join us in congratulating our new Program Co-Leaders and stay tuned for the groundbreaking work they lead at @UCCancerCenter✨ #CancerResearch #ExpertLeadership #InnovativeCollaboration #MolecularMechanisms #Pathology #Genetics #UCCCCLeaders #Healthcare #MedicalResearch

New paper out of the @KlineLabUChi @UChicagoMed about function of T cells in the Hodgkin tumor microenvironment and implications on mechanism of PD1/PDL1 checkpoint blockade. #lymsm cc @SoniSmithMD @jovianyu @gvencut1 aacrjournals.org/cancerimmunolr…

@UChicagoHemOnc @UCCancerCenter

We're excited to make our lab page debut sharing some exciting new work from lab members Xiufen Chen and lab alum @jovianyu in @CIR_AACR evaluating phenotypic and functional T cell states in cHL samples along with T cell clonality at the single cell level! aacrjournals.org/cancerimmunolr…